Fragile X at a turning point: Breaking through the clinical bottleneck
In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Hilary Rosselot, Executive Director, National Fragile X Foundation
Jordi Fàbrega, Co-Founder & CEO, CONNECTA Therapeutics
Disclaimer: The views expressed in this discussion by guests are…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.